

Margareta Reis

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5286980/margareta-reis-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

33
papers

1,143
citations

20
h-index

33
g-index

34
ext. papers

1,291
ext. citations

3.8
avg. IF

4.38
L-index

#	Paper	IF	Citations
33	Expectancy effects on serotonin and dopamine transporters during SSRI treatment of social anxiety disorder: a randomized clinical trial. <i>Translational Psychiatry</i> , 2021 , 11, 559	8.6	5
32	A Relative Bioavailability Study of Two Misoprostol Formulations Following a Single Oral or Sublingual Administration. <i>Frontiers in Pharmacology</i> , 2020 , 11, 50	5.6	1
31	Recognition of personality disorder and anxiety disorder comorbidity in patients treated for depression in secondary psychiatric care. <i>PLoS ONE</i> , 2020 , 15, e0227364	3.7	11
30	A Compilation of Serum Concentrations of 12 Antipsychotic Drugs in a Therapeutic Drug Monitoring Setting. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 348-356	3.2	18
29	Drug use in pregnant women-a pilot study of the coherence between reported use of drugs and presence of drugs in plasma. <i>European Journal of Clinical Pharmacology</i> , 2018 , 74, 535-539	2.8	5
28	Impact of generic substitution on levetiracetam serum concentration-A prospective study in an outpatient setting. <i>Epilepsy Research</i> , 2017 , 134, 54-61	3	11
27	Do You Believe It? Verbal Suggestions Influence the Clinical and Neural Effects of Escitalopram in Social Anxiety Disorder: A Randomized Trial. <i>EBioMedicine</i> , 2017 , 24, 179-188	8.8	26
26	Combining escitalopram and cognitive-behavioural therapy for social anxiety disorder: randomised controlled fMRI trial. <i>British Journal of Psychiatry</i> , 2016 , 209, 229-35	5.4	25
25	Antipsychotics - Postmortem fatal and non-fatal reference concentrations. <i>Forensic Science International</i> , 2016 , 266, 91-101	2.6	17
24	Ongoing Pharmacological Management of Chronic Pain in Pregnancy. <i>Drugs</i> , 2016 , 76, 915-24	12.1	29
23	Use of tramadol in early pregnancy and congenital malformation risk. <i>Reproductive Toxicology</i> , 2015 , 58, 246-51	3.4	26
22	On the pedagogy of pharmacological communication: a study of final semester health science students. <i>BMC Medical Education</i> , 2015 , 15, 186	3.3	3
21	The understanding of core pharmacological concepts among health care students in their final semester. <i>BMC Medical Education</i> , 2015 , 15, 235	3.3	9
20	Sedative and hypnotic drugs--fatal and non-fatal reference blood concentrations. <i>Forensic Science International</i> , 2014 , 236, 138-45	2.6	27
19	Combined use of selective serotonin reuptake inhibitors and sedatives/hypnotics during pregnancy: risk of relatively severe congenital malformations or cardiac defects. A register study. <i>BMJ Open</i> , 2013 , 3,	3	34
18	The use of central nervous system active drugs during pregnancy. <i>Pharmaceuticals</i> , 2013 , 6, 1221-86	5.2	101
17	Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy. <i>Journal of Clinical Psychopharmacology</i> , 2012 , 32, 608-14	1.7	28

16	Steady-state concentrations of mirtazapine, N-desmethyilmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour. <i>Clinical Pharmacokinetics</i> , 2009 , 48, 63-70	6.2	35
15	Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. <i>Therapeutic Drug Monitoring</i> , 2009 , 31, 42-56	3.2	102
14	Maternal use of antipsychotics in early pregnancy and delivery outcome. <i>Journal of Clinical Psychopharmacology</i> , 2008 , 28, 279-88	1.7	149
13	Therapeutic drug monitoring of ziprasidone in a clinical treatment setting. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 682-8	3.2	15
12	Therapeutic drug monitoring of escitalopram in an outpatient setting. <i>Therapeutic Drug Monitoring</i> , 2007 , 29, 758-66	3.2	36
11	Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder: a 6-month therapeutic drug monitoring study. <i>Therapeutic Drug Monitoring</i> , 2005 , 27, 469-77	3.2	22
10	Compliance with SSRI medication during 6 months of treatment for major depression: an evaluation by determination of repeated serum drug concentrations. <i>Journal of Affective Disorders</i> , 2004 , 82, 443-6	6.6	15
9	Serum disposition of sertraline, N-desmethylertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression. <i>Human Psychopharmacology</i> , 2004 , 19, 283-91	2.3	35
8	Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997. <i>Therapeutic Drug Monitoring</i> , 2003 , 25, 183-91	3.2	50
7	Serum levels of citalopram and its main metabolites in adolescent patients treated in a naturalistic clinical setting. <i>Journal of Clinical Psychopharmacology</i> , 2002 , 22, 406-13	1.7	17
6	Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. <i>Therapeutic Drug Monitoring</i> , 2002 , 24, 518-26	3.2	92
5	Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. <i>Therapeutic Drug Monitoring</i> , 2002 , 24, 545-53	3.2	57
4	Serum concentrations of fluoxetine in the clinical treatment setting. <i>Therapeutic Drug Monitoring</i> , 2001 , 23, 139-47	3.2	48
3	Enantioselective analysis of citalopram and metabolites in adolescents. <i>Therapeutic Drug Monitoring</i> , 2001 , 23, 658-64	3.2	40
2	Therapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting. <i>Therapeutic Drug Monitoring</i> , 2000 , 22, 446-54	3.2	54
1	Pharmacological treatment of mental health problems in pregnancy and lactation 122-136		